← Back to Patent Explorer
EP0533433A1 Expired / Lapsed EP ⏱️ 0.0 years remaining

Use of rapamycin for the manufacture of a medicament for the treatment of immunoinflammatory diseases

Assignee: Wyeth
•
Filing: 1992-09-15
•
Granted: —
•
Expires: 2012-09-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention provides a method of treating immunoinflammatory skin or bowel disease in a mammal in need thereof which comprises administering an antiimmunoinflammatory amount of rapamycin, alone or in combination with cyclosporin A, orally, parenterally, intranasally, intrabronchially, topically, transdermally, or rectally. As such, rapamycin, alone or in combination with cyclosporin A, is useful in treating skin deseases such as psoriasis, atopic dermatitis, contact dermatitis, exczematous dermatitis, seborrheic dermatitis, Lichen planus, Pemphigus, bulus pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythmas, cutaneous eosinphilias, and the like; and bowel disease such as inflammatory bowel disease.

Inventors

  • 👤 Craig Eugene Caufield
  • 👤 John Henry Musser
  • 👤 Surendra Nath Sehgal

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-10-28 14:42
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K38/00; A61K38/04; A61K38/12; A61K38/13; A61P; A61P1/00; A61P17/00; A61P17/06; A61P37/00

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 21 words
Use of rapamycin in the manufacture of a medicament for use in treating immunoinflammatory skin or bowel disease in a mammal.
Claim 2
Dependent Claim 16 words
A use according to Claim 1 in which rapamycin is administered in combination with cyclosporin A.
Claim 3
Dependent Claim 25 words
A use according to Claim 1 or Claim 2 in which the medicament is adapted for administration orally, parenterally, intranasally, intrabronchially, topically, transdermally or rectally.
Claim 4
Dependent Claim 40 words
A use according to any one of Claims 1 to 3 in which the skin disease is psoriasis, atopic dermatitis, contact dermatitis, exczematous dermatitis, seborrheic dermatitis, Lichen planus, Phemphigus, bulus pemphigoid, Epidermolysis bullosa, urticaria, angiodema, vasculitide, erythma or cutaneous eosinphilia.
Claim 5
Dependent Claim 31 words
A use according to any one of Claims 1 to 3 in which the medicament for providing symptomatic relief of, preventing the progression of, or eradicating immunoinflammatory skin or bowel disease.
Claim 6
Dependent Claim 21 words
A use as claimed in any one of Claims 1 to 5 in which the medicament is in unit dosage form.
Claim 7
Dependent Claim 28 words
A use according to Claim 6 in which the unit dose comprises 0.001 to 100 mg/kg of rapamycin based on the weight of the mammal to be treated.
Claim 8
Dependent Claim 28 words
A use according to Claim 6 in which the unit dose comprises 0.1 to 50 mg/kg of rapamycin based on the weight of the mammal to be treated.
Claim 9
Dependent Claim 30 words
A use or method according to Claim 6 in which the unit dose comprises 0.3 to 25 mg/kg of rapamycin based on the weight of the mammal to be treated.

References Cited (Backward Citations)

EP0315978A2 Cited
US5023263A Cited
WO1992002229A1 Cited

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag